Estrella Immunopharma, Inc.
ESLA
$0.905
$0.0171.91%
| Weiss Ratings | ESLA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | ESLA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ESLA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.50 | |||
| Price History | ESLA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 19.08% | |||
| 30-Day Total Return | -5.73% | |||
| 60-Day Total Return | -15.42% | |||
| 90-Day Total Return | -12.98% | |||
| Year to Date Total Return | -19.20% | |||
| 1-Year Total Return | -23.31% | |||
| 2-Year Total Return | -91.45% | |||
| 3-Year Total Return | -90.94% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -72.51% | |||
| 52-Week Low % Change | 40.95% | |||
| Price | ESLA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $3.23 | |||
| 52-Week Low Price | $0.63 | |||
| 52-Week Low Price (Date) | Oct 31, 2024 | |||
| 52-Week High Price (Date) | Jul 26, 2024 | |||
| Valuation | ESLA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 32.12M | |||
| Enterprise Value | 31.20M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.24 | |||
| Earnings Per Share Growth | -99.21% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 43.11 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.91 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -3.54 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | ESLA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 36.21M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ESLA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 510 318 9098 | |||
| Address | 5858 Horton Street EmeryVille, CA 94608 | |||
| Website | www.estrellabio.com | |||
| Country | United States | |||
| Year Founded | 2006 | |||
| Profitability | ESLA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | ESLA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -35.45% | |||
| Return on Equity | -- | |||
| Income Statement | ESLA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -8.82M | |||
| Net Income (TTM) | -8.82M | |||
| Net Income Avl. to Common (TTM) | -8.82M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -80.52% | |||
| EPS Diluted (TTM) | -0.24 | |||
| EPS Diluted Growth (Q YOY) | 94.75% | |||
| Balance Sheet | ESLA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 1.80M | |||
| Cash Per Share (Q) | $0.05 | |||
| Total Current Assets (Q) | 2.24M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 746.30K | |||
| Current Ratio (Q) | 0.748 | |||
| Book Value Per Share (Q) | $0.02 | |||
| Total Assets (Q) | 3.74M | |||
| Total Current Liabilities (Q) | 2.99M | |||
| Total Debt (Q) | 4.00K | |||
| Total Liabilities (Q) | 2.99M | |||
| Total Common Equity (Q) | 746.30K | |||
| Cash Flow | ESLA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 5.07M | |||
| Cash from Financing (TTM) | -7.40M | |||
| Net Change in Cash (TTM) | -20.34M | |||
| Levered Free Cash Flow (TTM) | -14.71M | |||
| Cash from Operations (TTM) | -18.01M | |||
